文献速递神经介入DSA

Neuroform Atlas 支架辅助弹簧圈栓塞治疗颅内动脉瘤的多中心上市后分析

Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-05-28

基于11个学术中心的回顾性病历分析,纳入2018年1月至2019年6月FDA豁免后使用Neuroform Atlas支架治疗的128例患者共128个动脉瘤(138枚支架)。技术并发症发生率4.7%,症状性血栓栓塞性卒中2.3%,症状性出血0.8%;出院时和末次随访时Raymond-Roy分级I-II级分别达82.9%和89.5%,末次随访mRS≤2者占96.9%。该多中心分析提供了Neuroform Atlas支架治疗颅内动脉瘤的真实世界安全性和有效性数据。

要点

  • 宽颈动脉瘤占80.5%,小动脉瘤(<7 mm)占76.6%,分叉部常见部位为基底动脉尖28.9%、前交通动脉27.3%、大脑中动脉分叉12.5%。
  • 技术并发症4.7%,症状性血栓栓塞性卒中2.3%,症状性出血0.8%;末次随访mRS≤2者96.9%。
  • 出院时Raymond-Roy分级I-II级82.9%,末次随访升至89.5%。

关键影像表现/征象

  • 宽颈动脉瘤占80.5%,小动脉瘤(<7 mm)占76.6%。
  • 分叉部动脉瘤位置:基底动脉尖28.9%,前交通动脉27.3%,大脑中动脉分叉12.5%。
  • 92.2%的病例使用单枚支架,59.4%的病例使用单根导管完成支架置入和弹簧圈栓塞。

诊断标准与关键数值

  • 出院时Raymond-Roy分级I和II级达82.9%,末次随访达89.5%。
  • 末次随访mRS≤2者占96.9%。
  • 即刻Raymond-Roy分级与动脉瘤位置相关(P < .0001),与治疗时破裂状态相关(P = .03)。

临床应用与阅片要点

  • 术后评估应参照Raymond-Roy分级报告栓塞程度,出院时I-II级82.9%,末次随访89.5%。
  • 技术并发症发生率4.7%,症状性血栓栓塞性卒中2.3%,症状性出血0.8%,阅片时需关注相关征象。
  • 末次随访mRS≤2者96.9%,提示多数患者临床预后良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent.

MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up.

RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (<7 mm, 76.6%), and bifurcation aneurysm location (basilar apex, 28.9%; anterior communicating artery, 27.3%; and middle cerebral artery bifurcation, 12.5%) were common. A single stent was used in 92.2% of cases, and a single catheter for both stent placement and coiling was used in 59.4% of cases. Technical complications during stent deployment occurred in 4.7% of cases; symptomatic thromboembolic stroke, in 2.3%; and symptomatic hemorrhage, in 0.8%. Favorable Raymond grades (Raymond-Roy occlusion classification) I and II were achieved in 82.9% at discharge and 89.5% at last follow-up. mRS ≤2 was determined in 96.9% of patients at last follow-up. The immediate Raymond-Roy occlusion classification grade correlated with aneurysm location (P < .0001) and rupture status during treatment (P = .03).

CONCLUSIONS: This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Burkhardt JK, Srinivasan V, Srivatsan A, et al. Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms. AJNR Am J Neuroradiol. 2020. PMID: 32467183. doi:10.3174/ajnr.A6581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。